Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4695 - Clinical significance of 18F-fluorodeoxyglucose-positron emission tomography-positive lymph nodes to outcomes of trimodal therapy for esophageal squamous cell carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Staging and Imaging

Tumour Site

Oesophageal Cancer

Presenters

Yoichi Hamai

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

Y. Hamai1, M. Emi1, Y. Ibuki1, M. Okada2

Author affiliations

  • 1 Surgical oncology, Institute of Biomedical & Health Sciences, Hiroshima University, 734-0037 - Hiroshima/JP
  • 2 Surgical oncology, Hiroshima University, 734-8551 - Hiroshima/JP
More

Abstract 4695

Background

The clinical significance of lymph node (LN) status determined by preoperative 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has not been investigated in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (NCRT) followed by surgery (trimodal therapy).

Methods

We reviewed 132 consecutive patients with ESCC who were preoperatively evaluated using FDG-PET before and after NCRT to analyze associations among LN status according to PET findings, pathological LN metastasis and the prognosis of ESCC after trimodal therapy.

Results

PET-positive LN both before and after NCRT comprised significant predictive markers of pathological LN metastasis (sensitivity, specificity and accuracy: 84.5%; 40.5%; 59.8% [p = 0.002] before, and 27.6%, 87.8% and 61.4% [p = 0.02] after NCRT, respectively). The numbers of LN evaluated using PET before and after NCRT and of pathological metastatic LN were significantly associated. Univariate and multivariable analyses selected LN status determined by PET before NCRT as a significant independent predictor of both recurrence-free (LN negative vs. positive: hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.02 – 3.23; p = 0.045) and overall survival (HR, 2.62; 95% CI, 1.29 – 5.30, p = 0.01).

Conclusions

The status of LN determined by preoperative FDG-PET is significantly associated with pathological LN status and the prognosis of ESCC with trimodal therapy. Thus, FDG-PET is a useful diagnostic tool with which to preoperatively predict pathological LN metastasis and survival among patients with ESCC.

Clinical trial identification

Legal entity responsible for the study

Hiroshima University.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.